View in EDS HTML Full Text PDF Full Text

Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.

Saved in:
Bibliographic Details
Title: Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.
Authors: Wang, Kun1 (AUTHOR), Pan, Chaohsuan2 (AUTHOR), Xu, Fengyan1 (AUTHOR), Tse, Archie N.2 (AUTHOR), Sheng, Yucheng2 (AUTHOR) shengyucheng@cstonepharma.com
Source: British Journal of Clinical Pharmacology. Mar2025, Vol. 91 Issue 3, p748-760. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 183984982
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Wang%2C+Kun%22">Wang, Kun</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pan%2C+Chaohsuan%22">Pan, Chaohsuan</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xu%2C+Fengyan%22">Xu, Fengyan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tse%2C+Archie+N%2E%22">Tse, Archie N.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sheng%2C+Yucheng%22">Sheng, Yucheng</searchLink><relatesTo>2</relatesTo> (AUTHOR)<i> shengyucheng@cstonepharma.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22British+Journal+of+Clinical+Pharmacology%22">British Journal of Clinical Pharmacology</searchLink>. Mar2025, Vol. 91 Issue 3, p748-760. 13p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=183984982
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bcp.16276
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 13
        StartPage: 748
    Titles:
      – TitleFull: Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang, Kun
      – PersonEntity:
          Name:
            NameFull: Pan, Chaohsuan
      – PersonEntity:
          Name:
            NameFull: Xu, Fengyan
      – PersonEntity:
          Name:
            NameFull: Tse, Archie N.
      – PersonEntity:
          Name:
            NameFull: Sheng, Yucheng
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: Mar2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 03065251
          Numbering:
            – Type: volume
              Value: 91
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: British Journal of Clinical Pharmacology
              Type: main
ResultId 1